Sort   by:  
 Page size 
TranscriptomicsTranscriptomic response to ex vivo IL33 stimulation of blood eosinophils from mepolizumab- or omalizumab-treated patients
Coding RNA expression of blood eosinophils from mepolizumab- or omalizumab-treated patients stimulated ex vivo with IL-33 for 6 hours and of directly processed non-stimulated blood eosinophils from the same samples (paired design)
ORGANISM(S): Homo sapiens 
2021-12-17 | E-MTAB-10189 | biostudies-arrayexpress
TranscriptomicsComparison of coding RNA expression of blood eosinophils from mepolizumab- or omalizumab-treated severe asthmatic patients and from healthy controls
RNA-seq comparison of coding RNA expression in blood eosinophils from patients with severe allergic eosinophilic asthma treated with mepolizumab with those of healthy controls and matched severe asthmatic patients receiving omalizumab.
ORGANISM(S): Homo sapiens 
2021-12-17 | E-MTAB-10190 | biostudies-arrayexpress
UnknownLong-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.
Not available
S-EPMC12295670 | biostudies-literature
ProteomicsSerum proteomic profile of asthmatic patients after 6 months of Benralizumab and Mepolizumab treatment
Severe eosinophilic asthma is characterized by chronic airway inflammation, oxidative stress and elevated proinflammatory cytokines, especially IL-5. Mepolizumab and benralizumab are both humanized IgG antibodies directed against IL-5 signaling, directly acting on eosinophils count. Together with th...
ORGANISM(S): Homo sapiens (Human) 
2022-04-01 | PXD029793 | Pride
Apoc Severe eosinophilic asthma. Mepolizumab  benralizumab  ceruloplasmin  plasminogen  apoa1 
GenomicsExploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma
Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma
PRJNA1474833 | ENA
GenomicsMepolizumab-induced Changes in Nasal Methylome and Transcriptome to Predict Response in Asthma
Mepolizumab-induced Changes in Nasal Methylome and Transcriptome to Predict Response in Asthma
PRJNA1146373 | ENA
UnknownEfficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Not available
S-EPMC9579892 | biostudies-literature
GenomicsHigh-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab Treatment in Severe Asthma
High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab Treatment in Severe Asthma
PRJNA1302261 | ENA
TranscriptomicsHigh-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab Treatment in Severe Asthma
Background Although the type 2 biologics mepolizumab and dupilumab show clinical efficacy in severe asthma, their influence on circulating lymphocytes is largely unknown. Here, we studied their impact on type 2 lymphocytes in severe asthma. Methods We performed high-parameter flow cytometry analysis...
ORGANISM(S): Homo sapiens 
2025-08-06 | GSE304665 | GEO
TranscriptomicsExploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma
Objective: To evaluate the effects of mepolizumab therapy on the blood transcriptome in patients with severe eosinophilic asthma (SEA) and to determine whether changes in gene expression predict responsiveness to mepolizumab treatment. Methods: Fourteen consecutive patients diagnosed with SEA were p...
ORGANISM(S): Homo sapiens 
2026-06-08 | GSE334345 | GEO
Sort   by:  
 Page size